Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1Phase 2 Interventional Results available

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

NCT04199728
Conditions
Opiate Substitution Treatment, Opioid-Related Disorders
Interventions
Liraglutide Pen Injector, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Weight Management, Obesity, Nutritional Adequacy, Body Composition, Skin Health, Hunger and Satiety, GLP-1 Receptor Agonist Use
Interventions
Glow Shakes Premium Collagen Meal Replacement Intervention
Dietary Supplement
Lead sponsor
The Collagen Co. - GLP-1 Users
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Alcohol Use Disorder (AUD)
Interventions
Pemvidutide, Placebo
Drug · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 9 more
Conditions
Alcohol Use Disorder
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
622 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
19
States / cities
Long Beach, California • Palo Alto, California • West Los Angeles, California + 15 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Semaglutide Use in Elderly Obese Patients

NCT05302596
Conditions
Obesity, Aging
Interventions
Semaglutide Pen Injector
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
65 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Gastrointestinal Discomfort, Gastrointestinal Side Effects of GLP-1 Receptor Agonist Use, Nausea, Abdominal Pain, Bloating, Diarrhea, Constipation
Interventions
Placebo, Oxxynea® Supplement
Dietary Supplement
Lead sponsor
AB Mauri (UK) Limited,
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Opioid
Interventions
Semaglutide Pen Injector, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • Fall River, Massachusetts • New York, New York + 1 more
Conditions
Cocaine Use Disorder
Interventions
Semaglutide, Placebo, cognitive behavioral therapy (CBT).
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Conditions
Gastric Content Aspiration
Interventions
Esophagogastroduodenoscopy
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Recruiting No phase listed Observational Accepts healthy volunteers

Gestational Response, Outcomes, and Weight After GLP-1 Use

NCT07743567
Conditions
Pregnant Individuals, Obesity & Overweight, Gestational Weight Gain
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers

NCT03645408
Conditions
Alcohol Use Disorder
Interventions
Exenatide, Sham injection
Drug · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts